CommercialCoverageLow impact
08.01.26e, Enzyme Replacement Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (e.g., elapegademase-lvlr [Revcovi])
Independence Blue Cross·Allergy & Immunology, Pediatrics·Medical Policy
Effective date
Jan 2, 2026
We identified it
Jun 19, 2026
Summary
A new medical policy for enzyme replacement therapy using elapegademase-lvlr (Revcovi) for treating Adenosine Deaminase Severe Combined Immune Deficiency has been updated for commercial insurance plans. This affects billing and coverage criteria for this specialized immunodeficiency treatment.
Action Required
By January 2, 2026: Billing team should review the complete policy details at the provided URL to understand coverage criteria and any prior authorization requirements for elapegademase-lvlr (Revcovi) treatments. Update billing procedures for this rare immunodeficiency therapy as needed based on the full policy content.